The large, phase III FIGARO-DKD trial strengthen the evidence on cardiovascular benefit (CV) of the nonsteroidal mineralocorticoid receptor (MR) antagonist finerenone, in addition to its renal benefit, across a wide spectrum of patients with type 2 diabetes (T2D) and chronic kidney disease (CKD).
Beyond 1 year, the humanized monoclonal antibody mepolizumab maintained real-world efficacy and safety in patients with severe eosinophilic asthma in the REALITI-A cohort study, reports an expert at ERS 2021.
Adding cyclophosphamide to glucocorticoid treatment in patients with acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) was associated with a numerically increased risk of mortality, according to results of the phase III EXAFIP trial.
Treatment with MV130, a sublingual bacterial immunotherapy, reduces the number of exacerbations in patients with chronic obstructive pulmonary disease (COPD), according to a recent study presented at ERS 2021.
Gene-augmentation therapy with voretigene neparvovec (VN) appears to be safe and confers visual function benefits that persist up to 4 years in patients with biallelic RPE65 mutation-associated inherited retinal disease, as shown in an open-label phase III study.
A pooled safety analysis of two phase III DISCOVER trials demonstrated the favourable safety profile of the novel interleukin(IL)-23p19-specific monoclonal antibody guselkumab through 1 year for psoriatic arthritis (PsA).
Daily treatment with doxycycline did not shorten recovery time or reduce hospitalization or death in community-dwelling older adults with COVID-19, according to a study from the PRINCIPLE Collaborative Group.
Interim results of two phase III ORIENT trials presented at ESMO 2021 underscore the potential of a combination regimen comprising the PD-1 inhibitor sintilimab and chemotherapy (CT) as a first-line therapeutic alternative for gastrointestinal cancers, particularly advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (SCC) and gastric/gastroesophageal junction (G/GEJ) adenocarcinoma.